Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:43:50.673Z.
Consensus retrieved: 2026-10-06T18:02:16.749Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:43:50.673Z.
Quote observation: 2026-10-06T19:40:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5137b4856deab08b1171b62dbd6f0c7b956cbbc758e96459f42c43e497148cec
Forward PE Ratio (N/A) = Dated Quote Price ($71.43) / Consensus Forward EPS ($0.10)
FORWARD PE RATIO
N/A
GeneDx Holdings Corp.
Market Cap
$2.13B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GeneDx Holdings Corp. (WGS) | $2.13B | N/A |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 16.02 |
| Pharvaris N.V. (PHVS)vs › | $2.16B | N/A |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | N/A |
| Alvotech (ALVO)vs › | $2.07B | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.19B | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 74.91 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $71.43, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.10 | $0.10 – $0.10 | 4 | 714.3x |
| 2027-12-31 | $1.20 | $1.15 – $1.25 | 4 | 59.6x |
| 2028-12-31 | $1.78 | $-3.13 – $6.69 | 2 | 40.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
